col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: Journal of Hepatology
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―19 Association of chronic liver disease with the prognosis of COVID-19 patients Junyu Long, Xinting Sang, Haitao Zhao
2 [GO] 2021―Jul―17 SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis Theresa Kirchner, Elmar Jaeckel, Christine S. Falk, Britta Eiz-Vesper, Richard Taubert
3 [GO] 2021―Jul―15 Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury Antonio Saviano, Thomas F. Baumert
4 [GO] 2021―Jul―10 AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY? Francesca Lodato, Anna Larocca, Antonietta D’Errico, Vincenzo Cennamo
5 [GO] 2021―Jul―08 The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis? Cathy McShane, Clifford Kiat, Jonathan Rigby, Órla Crosbie
6 [GO] 2021―Jun―24 Intravenous ketamine is a risk factor for jaundice in Covid-19 patients Vincent Mallet, Vincent Mallet, Kilian Bock, Mourad Dellagi, Marion Tano, Virginie Siorat, et al. (+30)
7 [GO] 2021―Jun―22 Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?” Daniel Clayton-Chubb, Daniel Schneider, Elliot Freeman, William Kemp, Stuart K. Roberts
8 [GO] 2021―Jun―18 Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association? Chin Kimg Tan, Yu Jun Wong, Lai Mun Wang, Tiing Leong Ang, Rahul Kumar
9 [GO] 2021―Jun―17 Response to letter to the editor by Capecchi et al. “Comment to the letter of Bril F et al. “Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?” Fernando Bril, David M. Fettig
10 [GO] 2021―Jun―12 Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty? Maria-Carlota Londoño, Jordi Gratacós-Ginès, Joaquín Sáez-Peñataro
11 [GO] 2021―Jun―09 Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty Alba Rocco, Costantino Sgamato, Debora Compare, Gerardo Nardone
12 [GO] 2021―Jun―06 Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19 Ze-yang Ding, Gan-xun Li, Chang Shu, Ping Yin, Bixiang Zhang
13 [GO] 2021―May―28 High acceptance rate of COVID-19 vaccination in liver transplant recipients Edoardo G. Giannini, Simona Marenco
14 [GO] 2021―May―25 Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients Markus Cornberg, Christiane S. Eberhardt
15 [GO] 2021―May―14 Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020 Vincent Mallet, Nathanael Beeker, Samir Bouam, Philippe Sogni, Stanislas Pol, Vincent Mallet, et al. (+9)
16 [GO] 2021―May―13 Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy Matthew J. McConnell, Nao Kawaguchi, Reiichiro Kondo, Aurelio Sonzogni, Lisa Licini, Clarissa Valle, et al. (+19)
17 [GO] 2021―May―07 HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination? Javier Crespo, Álvaro Díaz-González, Joaquín Cabezas
18 [GO] 2021―May―05 Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?” Pier Leopoldo Capecchi, Pietro Enea Lazzerini, Stefano Brillanti
19 [GO] 2021―Apr―24 Risk stratification in hospitalized COVID-19 patients Angela Horvath, Theresa Lind, Natalie Frece, Herbert Wurzer, Vanessa Stadlbauer
20 [GO] 2021―Apr―24 Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study Jitao Wang, Zhiyun Hou, Jianxin Liu, Ye Gu, Yunhong Wu, Zhenhuai Chen, et al. (+39)
21 [GO] 2021―Apr―24 Letter regarding “association of liver abnormalities with in-hospital mortality in patients with COVID-19 Meng-Si Luo, Guan-Jiang Huang
22 [GO] 2021―Apr―21 Reply to: Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients Manuel Rodríguez-Perálvarez, Jordi Colmenero, Magdalena Salcedo
23 [GO] 2021―Apr―21 Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty? Fernando Bril, Sameer Al Diffalha, Mark Dean, David M. Fettig
24 [GO] 2021―Apr―21 Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Liane Rabinowich, Ayelet Grupper, Roni Baruch, Merav Ben-Yehoyada, Tami Halperin, Dan Turner, et al. (+6)
25 [GO] 2021―Apr―20 DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS Milan J. Sonneveld, Irene K. Veldhuijzen, Thijs van de Laar, Eline L.M. Op de Coul, Adriaan J. van der Meer
26 [GO] 2021―Mar―20 Liver Injury in COVID-19 - The culprit may not be COVID-19! Aditya Singh, Madhumita Premkumar, Virendra Singh
27 [GO] 2021―Mar―20 Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered Pierre Deltenre, Christophe Moreno, Eric Trépo
28 [GO] 2021―Mar―20 Let’s leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world Javier Crespo, Jeffrey V. Lazarus, Paula Iruzubieta, Federico García, Javier García-Samaniego
29 [GO] 2021―Feb―21 Intravenous ketamine and progressive cholangiopathy in Covid-19 patients Vincent Mallet
30 [GO] 2021―Feb―21 PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION Alessandra Bartoli, Stefano Gitto, Pamela Sighinolfi, Carmela Cursaro, Pietro Andreone
31 [GO] 2021―Feb―07 EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients Markus Cornberg, Maria Buti, Christiane S. Eberhardt, Paolo Antonio Grossi, Daniel Shouval
32 [GO] 2021―Feb―06 Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. Gwilym J. Webb, Andrew M. Moon, Eleanor Barnes, A. Sidney Barritt, Thomas Marjot
33 [GO] 2021―Jan―26 SARS-CoV-2 infection in patients with autoimmune hepatitis Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, Alfred S. Barritt, Matthew J. Armstrong, et al. (+9)
34 [GO] 2021―Jan―13 Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy Andrea Giacomelli, Gabriele Pagani, Federico Conti, Cinzia Bassoli, Massimo Galli
35 [GO] 2020―Dec―20 Impact of the COVID 19 Pandemic on HCV Elimination in Spain Maria Buti, Raquel Domínguez-Hernández, Miguel Angel Casado
36 [GO] 2020―Dec―19 Association of liver abnormalities with in-hospital mortality in patients with COVID-19 Ze-yang Ding, Gan-xun Li, Lin Chen, Chang Shu, Jia Song, Wei Wang, et al. (+22)
37 [GO] 2020―Dec―16 Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD Abraham S. Meijnikman, Sjoerd Bruin, Albert K. Groen, Max Nieuwdorp, Hilde Herrema
38 [GO] 2020―Nov―20 NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues Kamran Mushtaq, Muhammad Umair Khan, Fatima Iqbal, Deema Hussam Alsoub, Hammad Shabir Chaudhry, Fateen Ata, et al. (+7)
39 [GO] 2020―Oct―30 Reply to: ‘NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression-The debate continues’ Dong Ji, Gregory Cheng, George Lau
40 [GO] 2020―Oct―20 Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points Marcos F. Fondevila, Maria Mercado-Gómez, Amaia Rodríguez, Maria J. Gonzalez-Rellan, Paula Iruzubieta, Víctor Valentí, et al. (+8)
41 [GO] 2020―Oct―09 SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination Javier Crespo, Álvaro Díaz-González, Paula Iruzubieta, Susana Llerena, Joaquín Cabezas
42 [GO] 2020―Oct―08 COVID-19: discovery, diagnostics and drug development Tarik Asselah, David Durantel, Eric Pasmant, George Lau, Raymond F. Schinazi
43 [GO] 2020―Oct―06 Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study Thomas Marjot, Andrew M. Moon, Jonathan A. Cook, Sherief Abd-Elsalam, Costica Aloman, Matthew J. Armstrong, et al. (+24)
44 [GO] 2020―Sep―16 Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition Chikako Yamamoto, Junko Tanaka, Vichit Ork, Shintaro Nagashima, Channarena Chuon, Ko Ko, et al. (+2)
45 [GO] 2020―Sep―10 Health status of patients with Autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders (Belgium) Xavier Verhelst, Nicky Somers, Anja Geerts, Helena Degroote, Hans Van Vlierberghe
46 [GO] 2020―Sep―02 Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall Alexandre Balaphas, Kyriaki Gkoufa, Jeremy Meyer, Andrea Peloso, Aurélie Bornand, Thomas A. McKee, et al. (+2)
47 [GO] 2020―Aug―07 Authors’ reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19 Massimo Iavarone, Roberta D’Ambrosio, Pietro Lampertico
48 [GO] 2020―Aug―07 Impact of COVID-19 on global hepatitis C elimination efforts Sarah Blach, Loreta A. Kondili, Alessio Aghemo, Zongzhen Cai, Ellen Dugan, Chris Estes, et al. (+8)
49 [GO] 2020―Aug―01 Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. Jordi Colmenero, Manuel Rodríguez-Perálvarez, Magdalena Salcedo, Ana Arias-Milla, Alejandro Muñoz-Serrano, Javier Graus, et al. (+29)
50 [GO] 2020―Jul―27 Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination Jeffrey V. Lazarus, Camila A. Picchio, Shevanthi Nayagam, Scott Ratzan, Mark Thursz
51 [GO] 2020―Jul―13 SARS-CoV2 in patients on antiviral HBV and HCV therapy in Spain Sabela Lens, Mireia Miquel, Beatriz Mateos-Muñoz, Javier García-Samaniego, Xavier Forns
52 [GO] 2020―Jul―06 Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients Alexander Kroemer, Khalid Khan, Matthew Plassmeyer, Oral Alpan, M.A. Haseeb, Raavi Gupta, Thomas M. Fishbein
53 [GO] 2020―Jul―04 Reply to “Liver tests abnormalities in COVID-19: trick or treat?” Qingxian Cai, Lin Xu, Jun Chen
54 [GO] 2020―Jun―23 Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis Montserrat Fraga, Darius Moradpour, Florent Artru, Elodie Romailler, Jonathan Tschopp, Antoine Schneider, et al. (+5)
55 [GO] 2020―Jun―23 SARS-CoV-2 infection in liver-Author’s reply Yijin Wang, Fengmin Lu, Jingmin Zhao
56 [GO] 2020―Jun―20 Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? Gabriella Assante, Roger Williams, Neil Alexander Youngson
57 [GO] 2020―Jun―20 The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research Feng Gao, Zhi-Ming Huang
58 [GO] 2020―Jun―20 Characteristics of pregnant COVID-19 patients with liver injury Guangtong Deng, Furong Zeng, Lijuan Zhang, Hui Chen, Xiang Chen, Mingzhu Yin
59 [GO] 2020―Jun―20 Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19] Mohammed A. Medhat, Mohamed El Kassas
60 [GO] 2020―Jun―15 COVID-19 and Liver. Dinesh Jothimani, Radhika Venugopal, Mohammed Forhad Abedin, Ilankumaran Kaliamoorthy, Mohamed Rela
61 [GO] 2020―Jun―09 High rates of 30-day mortality in patients with cirrhosis and COVID-19 Massimo Iavarone, Roberta D’Ambrosio, Alessandro Soria, Michela Triolo, Nicola Pugliese, Paolo Del Poggio, et al. (+16)
62 [GO] 2020―Jun―02 SARS-CoV-2: is the liver merely a bystander to severe disease? Mansoor N. Bangash, Jaimin M. Patel, Dhruv Parekh, Nicholas Murphy, Rachel M. Brown, Ahmed M. Elsharkawy, et al. (+3)
63 [GO] 2020―May―28 Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2 Vincent De Smet, Stefaan Verhulst, Leo A. van Grunsven
64 [GO] 2020―May―27 Liver tests abnormalities in COVID-19: trick or treat? Edoardo Vespa, Nicola Pugliese, Daniele Piovani, Antonio Capogreco, Silvio Danese, Alessio Aghemo
65 [GO] 2020―May―23 SARS-CoV-2 related liver impairment - perception may not be the reality Cyriac Abby Philips, Rizwan Ahamed, Philip Augustine
66 [GO] 2020―May―23 An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise Claire Alexandra Chew, Shridhar Ganpathi Iyer, Alfred Wei Chieh Kow, Krishnakumar Madhavan, Andrea Sze Teng Wong, Karim J. Halazun, et al. (+18)
67 [GO] 2020―May―22 A Local Response to COVID-19 for Advanced Liver Disease: Current Model of Care, Challenges and Opportunities Marina Serper, Abraham Shaked, Kim M. Olthoff, Maarouf Hoteit, Brenda Appolo, K. Rajender Reddy
68 [GO] 2020―May―21 High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry Andrew M. Moon, Gwilym J. Webb, Costica Aloman, Matthew J. Armstrong, Tamsin Cargill, Renumathy Dhanasekaran, et al. (+13)
69 [GO] 2020―May―20 Lack of genetic evidence that fatty liver disease predisposes to COVID-19 Luca Valenti, Oveis Jamialahmadi, Stefano Romeo
70 [GO] 2020―May―12 Health status of patients with Autoimmune Liver Disease during SARS-CoV-2 outbreak in northern Italy Angelo Di Giorgio, Emanuele Nicastro, Camilla Speziani, Massimo De Giorgio, Luisa Pasulo, Bianca Magro, et al. (+2)
71 [GO] 2020―May―11 SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 Yijin Wang, Shuhong Liu, Hongyang Liu, Wei Li, Fang Lin, Lina Jiang, et al. (+16)
72 [GO] 2020―May―11 Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’ Dong Ji, Enqiang Qin, George Lau
73 [GO] 2020―May―06 Reply to “Clinical characteristics of COVID-19 patients with abnormal liver tests” Qingxian Cai, Jun Chen
74 [GO] 2020―May―06 Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease’ Dong Ji, Enqiang Qin, Jing Xu, Dawei Zhang, Gregory Cheng, Yudong Wang, George Lau
75 [GO] 2020―Apr―30 No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease Louise Biquard, Dominique Valla, Pierre-Emmanuel Rautou
76 [GO] 2020―Apr―27 Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis Yu-Jie Zhou, Kenneth I. Zheng, Xiao-Bo Wang, Hua-Dong Yan, Qing-Feng Sun, Ke-Hua Pan, et al. (+5)
77 [GO] 2020―Apr―27 Clinical characteristics of COVID-19 patients with abnormal liver tests Peng Chen, Benhong Zhou
78 [GO] 2020―Apr―17 Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury Xiaolong Qi, Chuan Liu, Zicheng Jiang, Ye Gu, Guo Zhang, Chuxiao Shao, et al. (+20)
79 [GO] 2020―Apr―14 COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care Elliot B. Tapper, Sumeet K. Asrani
80 [GO] 2020―Apr―14 Characteristics of Liver Tests in COVID-19 Patients Qingxian Cai, Deliang Huang, Hong Yu, Zhibin Zhu, Zhang Xia, Yinan Su, et al. (+10)
81 [GO] 2020―Apr―10 Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia Ana Lleo, Pietro Invernizzi, Ansgar W. Lohse, Alessio Aghemo, Marco Carbone
82 [GO] 2020―Apr―08 Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis Dong Ji, Enqiang Qin, Jing Xu, Dawei Zhang, Gregory Cheng, Yudong Wang, George Lau


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.011 sec